

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 September 2024 (26.09.2024)



(10) International Publication Number
WO 2024/193905 A1

(51) International Patent Classification:
A61K 39/29 (2006.01) *A61P 31/20* (2006.01)

(21) International Application Number:
PCT/EP2024/053631

(22) International Filing Date:
13 February 2024 (13.02.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
23162520.3 17 March 2023 (17.03.2023) EP

(71) Applicants: **HELMHOLTZ ZENTRUM MÜNCHEN - DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH)** [DE/DE]; Ingolstädter Landstraße 1, 85764 Neuherberg (DE). **TECHNISCHE UNIVERSITÄT MÜNCHEN** [DE/DE]; Arcisstr. 21, 80333 München (DE). **UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF** [DE/DE]; Martinistrasse 52, 20246 Hamburg (DE). **ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG** [DE/DE]; Friedrichstr. 39, 79098 Freiburg (DE).

(72) Inventors: **PROTZER, Ulrike**; Anzlgutstrasse 45, 81735 München (DE). **AMBIKE, Shubhankar**; c/o Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Ingolstädter Landstraße 1, 85764 Neuherberg (DE). **KOSINSKA, Anna Dagmara**; c/o Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Ingolstädter Landstraße 1, 85764 Neuherberg (DE). **THIELE, Frank**; c/o Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Ingolstädter Landstraße 1, 85764 Neuherberg (DE). **WIEGAND, Marian**; c/o Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH), Ingolstädter Landstraße 1, 85764 Neuherberg (DE). **KNOLLE, Percy**; Anzlgutstrasse 45, 81735 München (DE). **ADDO, Marylyn Martina**; c/o Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg (DE). **NASSAL, Michael**; Sonnenhalde 7, 79232 March (DE).

(74) Agent: **WEINZIERL, Gerhard** et al.; c/o Schiweck Weinzierl Koch, Ganghoferstrasse 68b, 80339 Munich (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: HBV ANTIGEN FORMULATION FOR TREATING HEPATITIS B

(57) Abstract: The disclosure provides methods and compositions for treating HBV. Disclosed is an HBcAg particle, comprising HBV core proteins from at least two different HBV genotypes, and a vaccine vector comprising a nucleotide sequence having $\geq 90\%$ sequence identity to SEQ ID NO: 5. Disclosed are respective pharmaceutical compositions and their uses in therapy, for medicament manufacture and a vaccination method. Said vaccination method comprises administering to a human (i) a first dose and (ii) a second dose of an HBcAg particle and of an HBsAg, and (iii) a dose of a vaccine vector that expresses a HBsAg from HBV genotype A, a HBcAg from HBV genotype D, a HBsAg having $\geq 90\%$ sequence identity to SEQ ID NO: 7, a HBcAg having $\geq 90\%$ sequence identity to SEQ ID NO: 8 or 17, and an RT domain having $\geq 90\%$ sequence identity to SEQ ID NO: 9.



WO 2024/193905 A1